1) Conteduca V, et al : Neuroendocrine differentiation in prostate cancer : current and emerging therapy strategies. Crit Rev Oncol Hematol 92 : 11-24, 2014
2) di Sant'Agnese PA : Neuroendocrine differentiation in prostatic carcinoma : An update on recent developments. Ann Oncol 12 : S135-S140, 2001
3) Volante M, et al : The grey zone between pure (neuro) endocrine and non- (neuro) endocrine tumours : a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch 449 : 499-506, 2006
4) Abbas F, et al : Small cell carcinoma of the bladder and prostate. Urology 46 : 617-630, 1995
5) Mori H, et al : Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer. Intern Med 57 : 3123-3128, 2018
6) Dizeyi N, et al : Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 7 : 91-98, 2002
7) Hansson J, et al : Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 53 : 50-59, 2002
8) Halmos G, et al : High Expression of Somatostatin Receptors and Messenger mRNA for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers. J Clin Endocrinol Metab 85 : 2564-2571, 2000
静注用セットインタビューフォーム https://www.pdradiopharma.com/wpeptip/wp-content/uploads/2022/04/diagnostic05-interview.pdf (2023年12月4日閲覧)
10) Krenning EP, et al : Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1] -octreotide. Ital J Gastroenterol Hepatol 31 Suppl 2 : S219-223, 1999
Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376 : 125-135, 2017
Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1) : final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22 : 1752-1763, 2021
13) Assadi M, et al : 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation. Clin Nucl Med 44 : 978-980, 2019